Published in Blood on August 13, 2013
The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature (2016) 2.31
Selective targeting of the stress chaperome as a therapeutic strategy. Trends Pharmacol Sci (2014) 1.12
Heat shock protein 90 controls HIV-1 reactivation from latency. Proc Natl Acad Sci U S A (2014) 0.95
Current status of treatment for primary effusion lymphoma. Intractable Rare Dis Res (2014) 0.93
Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease. Cell Chem Biol (2016) 0.92
Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. ACS Chem Biol (2014) 0.91
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. J Clin Invest (2015) 0.88
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell Rep (2015) 0.86
Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. J Clin Invest (2016) 0.82
The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment. Curr Hematol Malig Rep (2015) 0.82
Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71. J Labelled Comp Radiopharm (2016) 0.79
Targeting of prosurvival pathways as therapeutic approaches against primary effusion lymphomas: past, present, and Future. Biomed Res Int (2015) 0.77
How do viruses trick B cells into becoming lymphomas? Curr Opin Hematol (2014) 0.76
Contribution of viral mimics of cellular genes to KSHV infection and disease. Viruses (2014) 0.76
Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection. Antiviral Res (2013) 0.76
Naughty chaperone as a target for viral cancer. Blood (2013) 0.75
Integrated systems biology analysis of KSHV latent infection reveals viral induction and reliance on peroxisome mediated lipid metabolism. PLoS Pathog (2017) 0.75
Recent advances in understanding Kaposi's sarcoma-associated herpesvirus. F1000Res (2016) 0.75
Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. J Clin Invest (2017) 0.75
Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma. Mol Cancer Ther (2017) 0.75
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science (1994) 39.60
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 21.16
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev (2006) 15.09
G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature (1998) 5.24
Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci (2006) 4.04
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci (2007) 3.74
Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology (2004) 3.60
Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer (2010) 3.55
The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol (2000) 3.12
Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ (2006) 2.85
FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol (2009) 2.81
Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood (2000) 2.53
The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol (1998) 2.48
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med (2004) 2.39
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A (2009) 2.35
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med (2009) 2.27
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta (2011) 2.21
KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci (2003) 2.04
Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci U S A (2009) 1.91
Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One (2010) 1.86
Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers (2010) 1.67
Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol (2006) 1.63
NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood (2005) 1.56
Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res (2006) 1.49
Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J Infect Dis (1999) 1.44
Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol (2006) 1.40
Effects of NFkappaB activation on KSHV latency and lytic reactivation are complex and context-dependent. Virology (2008) 1.21
IL-10 inhibits the starvation induced autophagy in macrophages via class I phosphatidylinositol 3-kinase (PI3K) pathway. Mol Immunol (2010) 1.20
Regulation and autoregulation of the promoter for the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2004) 1.14
Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets (2003) 1.11
Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proc Natl Acad Sci U S A (2010) 1.07
Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV. Virology (2010) 1.02
Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1. Oncogene (2010) 0.99
Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog (2012) 0.95
The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation. J Pathol (2007) 0.94
Heat shock protein 90 is important for Sp1 stability during mitosis. J Mol Biol (2009) 0.93
The growth transformation of human B cells involves superinduction of hsp70 and hsp90. Virology (1993) 0.90
The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells. Biol Pharm Bull (2012) 0.85
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev (2002) 13.08
PRDM16 controls a brown fat/skeletal muscle switch. Nature (2008) 13.08
DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature (2007) 11.14
Histone demethylation by a family of JmjC domain-containing proteins. Nature (2005) 10.36
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Role of histone H2A ubiquitination in Polycomb silencing. Nature (2004) 9.48
Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol (2010) 9.24
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest (2005) 6.10
Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res (2006) 5.99
Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol Cell (2007) 5.78
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Mol Cell (2002) 5.59
JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell (2006) 5.54
Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol (2002) 5.53
The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature (2006) 5.51
Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev (2002) 5.43
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell (2004) 5.37
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
Histone deimination antagonizes arginine methylation. Cell (2004) 5.19
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
The proapoptotic factors Bax and Bak regulate T Cell proliferation through control of endoplasmic reticulum Ca(2+) homeostasis. Immunity (2007) 4.74
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
A molecular roadmap of reprogramming somatic cells into iPS cells. Cell (2012) 4.41
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20
TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature (2011) 4.16
Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr Biol (2002) 4.12
Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell (2002) 4.08
Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev (2002) 4.07
Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. Mol Cell (2005) 4.04
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood (2009) 4.00
Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol (2004) 3.90
Regulation of the brown and white fat gene programs through a PRDM16/CtBP transcriptional complex. Genes Dev (2008) 3.90
P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell (2002) 3.80
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell (2004) 3.77
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem (2002) 3.70
L3MBTL1, a histone-methylation-dependent chromatin lock. Cell (2007) 3.70
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell (2007) 3.68
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature (2011) 3.63
Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer (2010) 3.55
methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol (2012) 3.44
Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol Cell (2006) 3.39
Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell (2005) 3.39
An iron delivery pathway mediated by a lipocalin. Mol Cell (2002) 3.38
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell (2006) 3.31
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet (2009) 3.21
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol (2002) 3.13
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med (2004) 3.10
A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging (2004) 3.07
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell (2010) 3.05
mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol Cell (2003) 2.97
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol (2007) 2.90
WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature (2008) 2.86
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood (2008) 2.85
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
Ubiquitylation of histone H2B controls RNA polymerase II transcription elongation independently of histone H3 methylation. Genes Dev (2007) 2.81
The RNA processing exosome is linked to elongating RNA polymerase II in Drosophila. Nature (2002) 2.77
MTERF3 is a negative regulator of mammalian mtDNA transcription. Cell (2007) 2.76
SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature (2007) 2.76
mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Mol Cell Biol (2003) 2.72
The human PAF complex coordinates transcription with events downstream of RNA synthesis. Genes Dev (2005) 2.70
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol Cell Biol (2003) 2.66
A new role for Nogo as a regulator of vascular remodeling. Nat Med (2004) 2.63
Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol (2007) 2.57
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood (2012) 2.55
Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature (2007) 2.52
CG dinucleotide clustering is a species-specific property of the genome. Nucleic Acids Res (2007) 2.48
Isolation and mass spectrometry of transcription factor complexes. Methods (2002) 2.46
Tandem bromodomains in the chromatin remodeler RSC recognize acetylated histone H3 Lys14. EMBO J (2004) 2.46
Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol Cell (2009) 2.45
PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator. Mol Cell (2005) 2.44
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42